<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>LetibotulinumtoxinA (Letybo) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">LetibotulinumtoxinA (Letybo) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">LetibotulinumtoxinA (Letybo) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="142054" href="/d/html/142054.html" rel="external">see "LetibotulinumtoxinA (Letybo) (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F58508370"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Letybo</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58493706"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Neuromuscular Blocker Agent, Toxin</li></ul></div>
<div class="block doa drugH1Div" id="F58525454"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8eb1dc4e-2ed1-4de4-816f-2a2e63945806">Glabellar lines</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glabellar lines:</b>
<b>IM:</b> Inject 4 units into each of the 5 sites (2 injections in each corrugator muscle and 1 in the procerus muscle) for a total dose of 20 units per treatment session. Do not administer more frequently than every 3 months.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F58525456"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F58525457"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F58525455"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Not approved for use in patients ≥65 years of age.</p></div>
<div class="block adr drugH1Div" id="F58525496"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Upper respiratory tract infection (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Folliculitis, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum potassium</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, nausea, oral herpes simplex infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise, hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including bleeding at injection site, bruising at injection site, discomfort at injection site, hematoma at injection site, inflammation at injection site, injection-site infection, injection-site nodule, injection-site pruritus, pain at injection site, residual mass at injection site, swelling at injection site, tenderness at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, facial pain, facial paresis, hypoesthesia, migraine, pain, paresthesia, tension headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharoptosis, blepharospasm, conjunctival hemorrhage, dry eye syndrome, eye pain, eyelid edema, periorbital hematoma, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, pneumonia, sinus headache, streptococcal pharyngitis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, swelling</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, serum sickness)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Myasthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p></div>
<div class="block coi drugH1Div" id="F58493663"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to letibotulinumtoxinA or any component of the formulation; infection or inflammation at the proposed injection site(s).</p></div>
<div class="block war drugH1Div" id="F58525447"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis/hypersensitivity reactions: Serious and/or immediate hypersensitivity reactions (eg, anaphylaxis, serum sickness, urticaria, soft-tissue edema, dyspnea) have occurred (rare). If a reaction occurs, discontinue and institute immediate treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Use with caution in patients with cardiovascular disease; arrhythmia and myocardial infarction (some fatal) have been reported following administration of botulinum toxin products. Some of these patients had risk factors, including preexisting cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Distant spread of toxin effect: <b>[Canadian Boxed Warning]: The effects of letibotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dysphagia: Treatment can result in swallowing or breathing difficulties; may occur within hours to weeks and persist for several months and require use of a feeding tube. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Risk factors include small neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Dry eye, reduced tear production, reduced blinking, and corneal disorders may occur with botulinum toxins; persistent symptoms may require ophthalmologic evaluation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular disease: Avoid use in patients with myasthenia gravis. Use with caution in patients with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, Lambert-Eaton syndrome). Risk of adverse events, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise, may be increased.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use extreme caution in patients with preexisting respiratory disease; treatment with botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Serious breathing difficulties, including respiratory failure, have been reported. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Not approved for patients ≥65 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Product contains albumin and may carry a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: <b>[Canadian Boxed Warning]: The term “Unit” upon which dosing of letibotulinumtoxinA is based, is a specific measurement of toxin activity that is unique to the formulation of letibotulinumtoxinA. Therefore, the Units used to describe letibotulinumtoxinA activity are different from those used to describe that of other botulinum toxin preparations and the Units representing letibotulinumtoxinA activity are not interchangeable with other products.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[Canadian Boxed Warning]: Follow the recommended dosage and frequency of administration for letibotulinumtoxinA. </b>Do not inject into a blood vessel. Do not use more frequently than every 3 months.</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel:<b> [Canadian Boxed Warning]: LetibotulinumtoxinA should only be administered by physicians with the appropriate qualifications and experience in the use of botulinum toxin products. </b>Physicians should be familiar with the patient's anatomy and any alterations to the anatomy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection site: Use with caution if there is inflammation or excessive weakness or atrophy at the proposed injection site(s). Use with caution in patients who have surgical alterations to the facial anatomy, marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart.</p></div>
<div class="block geq drugH1Div" id="F58508368"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F58508371"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Letybo: 100 units (1 ea) [contains albumin human]</p></div>
<div class="block adm drugH1Div" id="F58525458"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM:</b> Use a 30- to 31-gauge needle to administer IM. Inject into each of the 5 sites (2 injections in each corrugator muscle and 1 injection in the mid-line procerus muscle). Ensure injected volume/dose is accurate and, where feasible, keep to a minimum. Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Do not inject closer than 1 cm above the supraorbital rim or the central eyebrow. Refer to manufacturer's labeling for additional administration details.</p></div>
<div class="block use drugH1Div" id="F58493662"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Glabellar lines:</b> Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults &lt;65 years of age.</p></div>
<div class="block mst drugH1Div" id="F58493708"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p>
<p style="text-indent:0em;margin-left:2em;">Botulinum products are not interchangeable; potency differences may exist between the products.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F58525398"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58525395"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the neuromuscular-blocking effect of Botulinum Toxin-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Botulinum Toxin-Containing Products may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of other Botulinum Toxin-Containing Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Muscle Relaxants (Centrally Acting): May enhance the adverse/toxic effect of Botulinum Toxin-Containing Products. Specifically, the risk for increased muscle weakness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Botulinum Toxin-Containing Products may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F58574090"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Because data related to the use of botulinum toxins for cosmetic procedures during pregnancy are limited, use is generally avoided (Garg 2022; Morgan 2006; Trivedi 2017).</p></div>
<div class="block brc drugH1Div" id="F58574091"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if letibotulinumtoxinA is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F58525460"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Difficulty with swallowing, speaking, breathing, or muscle weakness or paralysis in areas other than the targeted area; ophthalmic effects (eg, eye dryness, eye irritation, photophobia, changes in vision).</p></div>
<div class="block pha drugH1Div" id="F58525453"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">LetibotulinumtoxinA (botulinum toxin type A) is a neurotoxin, produced by <i>Clostridium botulinum</i>, spore-forming anaerobic bacillus, that blocks cholinergic transmission at the neuromuscular junction and inhibits the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by letibotulinumtoxinA.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35965909">
<a name="35965909"></a>Garg AM, Mysore V. Dermatologic and cosmetic procedures in pregnancy. <i>J Cutan Aesthet Surg.</i> 2022;15(2):108-117. doi:10.4103/JCAS.JCAS_226_20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letibotulinumtoxina-letybo-united-states-not-available-drug-information/abstract-text/35965909/pubmed" id="35965909" target="_blank">35965909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Letybo.1">
<a name="Letybo.1"></a>Letybo (letibotulinumtoxinA) [product monograph]. Toronto, Ontario, Canada: Croma Aesthetics Canada Ltd; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16361610">
<a name="16361610"></a>Morgan JC, Iyer SS, Moser ET, Singer C, Sethi KD. Botulinum toxin A during pregnancy: a survey of treating physicians.<i> J Neurol Neurosurg Psychiatry</i>. 2006;77(1):117-119. doi:10.1136/jnnp.2005.063792<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letibotulinumtoxina-letybo-united-states-not-available-drug-information/abstract-text/16361610/pubmed" id="16361610" target="_blank">16361610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28492048">
<a name="28492048"></a>Trivedi MK, Kroumpouzos G, Murase JE. A review of the safety of cosmetic procedures during pregnancy and lactation.<i> Int J Womens Dermatol.</i> 2017;3(1):6-10. doi:10.1016/j.ijwd.2017.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letibotulinumtoxina-letybo-united-states-not-available-drug-information/abstract-text/28492048/pubmed" id="28492048" target="_blank">28492048</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 142014 Version 7.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
